Vaccine最新文献

{"title":"Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).","authors":"Anthony M Marchese, Hadi Beyhaghi, Matthew D Rousculp, Vivian Huang, Xinxue Liu, Seth Toback, Saul N Faust","doi":"10.1016/j.vaccine.2024.126569","DOIUrl":"10.1016/j.vaccine.2024.126569","url":null,"abstract":"<p><p>Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126569"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of experimental vaccines is ethically permissible during public health emergencies.","authors":"Ignacio Mastroleo","doi":"10.1016/j.vaccine.2024.04.065","DOIUrl":"10.1016/j.vaccine.2024.04.065","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"125919"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina\" [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234].","authors":"Gonzalo Guiñazú, Julia Dvorkin, Sarwat Mahmud, Ranju Baral, Clint Pecenka, Romina Libster, Andrew Clark, Mauricio T Caballero","doi":"10.1016/j.vaccine.2024.126402","DOIUrl":"10.1016/j.vaccine.2024.126402","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126402"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.","authors":"Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S Kelkar, Shilpee Sharma, Pieter Pannus, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt, Margarida Braga, Leo Heyndrickx, Johan Michiels, Anaïs Thiriard, Anne Lemy, Thomas Baudoux, Marylène Vandevenne, Maria E Goossens, André Matagne, Isabelle Desombere, Kevin K Ariën, Margaret E Ackerman, Alain Le Moine, Arnaud Marchant","doi":"10.1016/j.vaccine.2024.126544","DOIUrl":"10.1016/j.vaccine.2024.126544","url":null,"abstract":"<p><strong>Background: </strong>Clinical risk factors of deficient immune responses to COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2 infection and vaccination in HDR have not been reported.</p><p><strong>Methods: </strong>A comprehensive analysis of antibody (Ab) and T cell responses to two doses of BNT162b2 mRNA vaccination was performed in 103 HDR, including 75 SARS-CoV-2 naive and 28 experienced patients, and in 106 healthy controls (HC) not undergoing HD, including 40 SARS-CoV-2 naive and 66 experienced subjects. Clinical risk factors associated with lower humoral and cellular immunity were analyzed in SARS-CoV-2 naive and experienced HDR by univariate and multivariate analyses.</p><p><strong>Results: </strong>Naive HDR had lower neutralizing and non-neutralizing antibody responses to vaccination than naive HC; lower vaccine responses were correlated with previous transplantation, immunosuppressive treatment, corticosteroid treatment, hypoalbuminemia, older age, hypertension, and negative response to hepatitis B vaccination. In contrast, vaccine responses of SARS-CoV-2 experienced HDR were similar to those of HC and were correlated with time between infection and vaccination and with previous transplantation, but not with the other risk factors associated with lower vaccine responses in naive HDR.</p><p><strong>Conclusion: </strong>COVID-19 vaccine responses are influenced by distinct risk factors in SARS-CoV-2 naive and experienced HDR. These observations have important implications for the understanding of vaccine-induced immunity and for the management of this vulnerable patient population.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126544"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.","authors":"Qiang Wang, Liuqing Yang, Lan Li, Shixin Xiu, Min Yang, Xuwen Wang, Yuan Shen, Weibing Wang, Leesa Lin","doi":"10.1016/j.vaccine.2024.126570","DOIUrl":"10.1016/j.vaccine.2024.126570","url":null,"abstract":"<p><strong>Introduction: </strong>Our study aimed to assess parents' perceptions of respiratory syncytial virus (RSV) and their attitudes towards the RSV vaccine in China.</p><p><strong>Method: </strong>The cross-section study was performed between August 21 and November 15, 2023, in Jiangsu province, eastern China. We collected socio-demographics, awareness, knowledge, perceptions of susceptibility and severity of RSV, and attitudes towards RSV vaccine using online survey questionnaire from parents of child aged ≤14 years old. The chi-square test and logistic regression model to explore the associated factors.</p><p><strong>Results: </strong>A total of 2135 participants were included. About 26.0 % indicated that they had never heard of RSV (556/2135) and were unaware that infants and young children are at a high risk of contracting RSV (557/2135). The proportion of parents with a child under 1 year of age who were unaware of RSV was notably higher than that of parents with children in other age groups. 42.9 % of parents (916/2135) showed low level of perceived susceptibility of contacting RSV infection for their child. 70.6 % of parents (1508/2135) expressed their willingness to vaccinate their child against RSV. The most common reason for refusing the RSV vaccine was \"Concern about vaccine's safety or side effects.\" 60.8 % of participants (1299/2135) considered a price of the RSV vaccine below 200 CNY (28 USD) as acceptable.</p><p><strong>Conclusion: </strong>The parents, particularly those with younger children, exhibited limited awareness and knowledge regarding RSV infection. Our study also showed the potential role of vaccine price as a barrier to the future use of RSV vaccine in China.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126570"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conceptual debates in the study of canine & feline vaccine hesitancy: A response to Haeder 2023.","authors":"Matt Motta, Gabriella Motta, Dominik Stecula","doi":"10.1016/j.vaccine.2024.126397","DOIUrl":"10.1016/j.vaccine.2024.126397","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126397"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions.","authors":"Melissa Rosenthal, Charles Stoecker, Andrew J Leidner, Bo-Hyun Cho, Tamara Pilishvili, Miwako Kobayashi","doi":"10.1016/j.vaccine.2024.126567","DOIUrl":"10.1016/j.vaccine.2024.126567","url":null,"abstract":"<p><strong>Background: </strong>In June 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all PCV-unvaccinated adults aged ≥65 years (age-based) and for adults aged 19-64 years with conditions that increase the risk for pneumococcal disease (risk-based). This recommendation replaced a previous recommendation for PPSV23 with or without 13-valent pneumococcal conjugate vaccine (PCV13) for these groups.</p><p><strong>Objective: </strong>We conducted a cost-effectiveness analysis of age-based and risk-based use of either PCV15 in series with PPSV23 or PCV20 alone when compared to previous recommendations.</p><p><strong>Methods: </strong>We utilized probabilistic cohort models of all 65-year-olds (age-based) and 19-year-olds (risk-based through age 64 years and age-based at age 65 years). A spreadsheet-based Monte Carlo simulation software was used to estimate immunization costs, medical costs, non-medical costs, and overall disease burden under different vaccine strategies. The model tracked inpatient invasive pneumococcal disease (IPD) and non-bacteremic pneumonia (NBP) in inpatient and outpatient settings. One-way sensitivity analyses incorporated indirect effects of prospective pediatric vaccination with PCV15 and PCV20 on adult IPD and NBP incidence. Costs were reported in 2021 US dollars. All future costs and outcomes were discounted at 3 % per year.</p><p><strong>Results: </strong>Age-based use of either PCV20 alone or PCV15 in series with PPSV23 at age 65 years were both shown to be cost-saving (improved health outcomes and saved costs). Combined cost-effectiveness of risk-based (19-64 years) plus age-based (65 years) (risk-and-age-based) use of PCV20 alone was cost-saving, whereas use of PCV15 in series with PPSV23 increased quality-adjusted life years (QALYs) but cost $412,111 (95 % CI: 270,295, 694,869) per QALY gained.</p><p><strong>Conclusion: </strong>In U.S. adults, replacing the previous recommendations with PCV20 alone or PCV15 in series with PPSV23 improved health outcomes. Except for risk-and-age-based use of PCV15 in series with PPSV23 that resulted in increased cost per QALY gained, the interventions also reduced costs.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126567"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of using the test-negative design to measure vaccine effectiveness of multi-pathogen combination vaccines targeting one syndrome.","authors":"Sara S Kim, Maria Garcia Quesada, Pragati V Prasad, Kristin N Nelson, Benjamin A Lopman, Elizabeth T Rogawski McQuade","doi":"10.1016/j.vaccine.2024.126520","DOIUrl":"10.1016/j.vaccine.2024.126520","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126520"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No person left behind: Understanding vaccine hesitancy in low- and middle-income countries.","authors":"Alvira Tyagi, Simar S Bajaj, Esther Njinembo Nayeu, Fatima Cody Stanford","doi":"10.1016/j.vaccine.2024.126446","DOIUrl":"10.1016/j.vaccine.2024.126446","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126446"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023.","authors":"Erica Liebermann, Melanie Kornides, Masako Matsunaga, Eungung Lim, Gregory Zimet, Gary Glauberman, Cable Kronen, Holly B Fontenot","doi":"10.1016/j.vaccine.2024.126571","DOIUrl":"10.1016/j.vaccine.2024.126571","url":null,"abstract":"<p><strong>Purpose: </strong>Explore mothers of adolescents' use of social media and the influence of social media on hesitancy regarding HPV vaccine.</p><p><strong>Methods: </strong>A national online survey of mothers of adolescents aged 9-17 years was conducted in August 2023, with participants recruited from an online research panel of US residents. The study examined socio-demographic factors, social media use patterns, and influence of social media and their association with HPV vaccine hesitancy.</p><p><strong>Results: </strong>Survey sample included 3968 mothers of adolescents. Specifically among the social media variables, multivariable analysis revealed that Facebook influence was negatively associated with HPV vaccine hesitancy (β = -0.016, 95 % confidence interval [CI] = (-0.029, -0.003), p = 0.019), while uncertainty about social media messages (veracity) (β = 0.067, 95 % CI = (0.021, 0.113), p = 0.004) were associated with increased vaccine hesitancy. No significant associations were found with the number of daily-used social media platforms or influence from other platforms.</p><p><strong>Discussion: </strong>Our findings highlight the impact of uncertainty about social media messages and its effect on parents' HPV vaccine hesitancy. Our findings also highlight the potential role of health care providers in reducing vaccine hesitancy during clinical encounters. Future research is needed to better understand the elements (content, approach, platforms) of effective social media communication interventions to decrease vaccine hesitancy and improve HPV vaccination rates among adolescents in the US.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126571"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}